Revlimid Indication:

For the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Revlimid Mechanism Of Action:

The mechanism of action of lenalidomide remains to be fully characterized, however it has been demonstrated that lenalidomide inhibits the expression of cyclooxygenase-2 (COX-2), but not COX-1, in vitro.

Revlimid Drug Interactions:

Not Available

Revlimid Food Interactions:

Not Available

Revlimid Generic Name:


  • CDC 501
  • CC-5013
  • IMiD3

Drug Type:

Small Molecule; Approved; Investigational


Rapidly absorbed following oral administration, with maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. Co-administration with food does not alter the extent of absorption (AUC) but does reduce the maximal plasma concentration (Cmax) by 36%. The pharmacokinetic disposition of lenalidomide is linear.

Toxicity (Overdose):

The most frequently reported adverse events were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions.

Protein Binding:



The metabolic profile of lenalidomide in humans has not been studied. In healthy volunteers, approximately two-thirds of lenalidomide is eliminated unchanged through urinary excretion. The process exceeds the glomerular filtration rate and therefore is partially or entirely active.

Half Life:

3 hours

Dosage Forms of Revlimid:

Not Available

Chemical IUPAC Name:


Organisms Affected:

Humans and other mammals

Revlimid to general, pharmacology

General, pharmacology..